D. E. Shaw & Co. Inc. trimmed its stake in shares of Cryolife Inc (NYSE:CRY) by 17.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,654 shares of the medical equipment provider’s stock after selling 2,034 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Cryolife were worth $274,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. BlackRock Inc. grew its holdings in Cryolife by 2.8% in the fourth quarter. BlackRock Inc. now owns 5,533,113 shares of the medical equipment provider’s stock valued at $157,030,000 after purchasing an additional 152,026 shares during the period. Vanguard Group Inc grew its holdings in Cryolife by 2.7% in the third quarter. Vanguard Group Inc now owns 2,017,304 shares of the medical equipment provider’s stock valued at $71,009,000 after purchasing an additional 53,676 shares during the period. Vanguard Group Inc. grew its holdings in Cryolife by 2.7% in the third quarter. Vanguard Group Inc. now owns 2,017,304 shares of the medical equipment provider’s stock valued at $71,009,000 after purchasing an additional 53,676 shares during the period. Bank of New York Mellon Corp grew its holdings in Cryolife by 11.9% in the third quarter. Bank of New York Mellon Corp now owns 459,275 shares of the medical equipment provider’s stock valued at $16,166,000 after purchasing an additional 48,994 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Cryolife by 11.3% in the fourth quarter. Geode Capital Management LLC now owns 366,746 shares of the medical equipment provider’s stock valued at $10,408,000 after purchasing an additional 37,096 shares during the period. 71.31% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have commented on the company. Zacks Investment Research lowered Cryolife from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. Needham & Company LLC assumed coverage on Cryolife in a report on Wednesday, February 27th. They issued a “hold” rating and a $29.65 price objective on the stock. Northland Securities reissued a “buy” rating and issued a $32.00 price objective on shares of Cryolife in a report on Thursday, January 17th. Finally, ValuEngine raised Cryolife from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $32.16.

In other news, VP Amy Horton sold 6,666 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $29.15, for a total value of $194,313.90. Following the transaction, the vice president now owns 103,713 shares in the company, valued at $3,023,233.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronald D. Mccall sold 6,200 shares of the firm’s stock in a transaction that occurred on Thursday, February 21st. The shares were sold at an average price of $29.26, for a total value of $181,412.00. Following the completion of the transaction, the director now owns 137,699 shares in the company, valued at approximately $4,029,072.74. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

NYSE CRY opened at $29.97 on Tuesday. The company has a market capitalization of $1.11 billion, a PE ratio of 115.27 and a beta of 0.54. Cryolife Inc has a 1-year low of $21.35 and a 1-year high of $36.05. The company has a current ratio of 5.19, a quick ratio of 3.87 and a debt-to-equity ratio of 0.81.

Cryolife (NYSE:CRY) last released its earnings results on Wednesday, February 13th. The medical equipment provider reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.07). The firm had revenue of $67.80 million during the quarter, compared to analysts’ expectations of $67.10 million. Cryolife had a negative net margin of 1.45% and a positive return on equity of 3.49%. On average, research analysts predict that Cryolife Inc will post 0.31 earnings per share for the current fiscal year.

WARNING: “D. E. Shaw & Co. Inc. Has $274,000 Position in Cryolife Inc (CRY)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2019/04/16/d-e-shaw-co-inc-has-274000-position-in-cryolife-inc-cry.html.

Cryolife Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Featured Story: Can individual investors take part in an IPO?

Want to see what other hedge funds are holding CRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cryolife Inc (NYSE:CRY).

Institutional Ownership by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.